---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-002708"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:16:01.457922+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q4 core revenue +20%, total rev -45% on milestone comp; FY2025 core growth 8-15%

## Summary
- Q4 2024 total revenue $8.7M (-45% YoY); core revenue ex-milestones $8.6M (+20%); net loss $10.6M vs $5.3M.
- FY2024 total revenue $38.6M (-6%); core revenue $32.5M (+9%); gross margin 82%; net loss $41.1M vs $37.9M.
- Ended 2024 with $190.3M cash; 28 active SPLs (up from 23), 18 clinical SPL programs, 1 commercial.
- 2025 guidance: core revenue growth 8-15% (incl SeQure Dx); SPL rev ~$5M; cash target $160M year-end.
- Signed record six SPLs in 2024; added TG Therapeutics early 2025; SeQure Dx acquisition integrated.

## SEC filing metadata
- accession: 0001558370-25-002708
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837025002708/0001558370-25-002708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837025002708/mxct-20250311x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-002708
- JSON: https://secwatch.observer/filing/0001558370-25-002708.json
- Plain text: https://secwatch.observer/filing/0001558370-25-002708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.